TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06777069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leucocyte and platelet rich fibrin membrane application
Description: Leukocyte and platelet rich membrane, obtained by centrifuging 10 ml of venous blood collected from the patient's antecubital vein, was sutured to the donor sites.
Study: NCT01946711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Nasal spray
Study: NCT01873794

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bright white light

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dim red light
Study: NCT00209313

Intervention type: DRUG
Group type: OTHER
Intervention: Acyclovir
Description: Acyclovir 800 mg twice daily or placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Acyclovir
Description: Acyclovir 800 mg twice daily or placebo
Study: NCT00598689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% hypromellose
Description: 0.3% hypromellose four times a day for 5 days prior to LASIK surgery
Study: NCT02239718

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2-unit cantilevered resin bonded bridge
Description: Use one tooth as abutment tooth to replace one adjacent missing tooth

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3-unit fixed movable resin bonded bridge
Description: Use teeth from both side of the missing tooth space to replace a tooth. The prosthesis is cast in two piece and connected with a fixed-movable joint (semi-precision, allow degree of movement).
Study: NCT02629510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tachosil
Study: NCT02812810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active rTMS

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham rTMS
Study: NCT03215446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maintenance of anaesthesia with propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maintenance of anaesthesia with sevoflurane
Study: NCT02374827

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard postpartum tubal ligation
Description: Patients will undergo a standard postpartum tubal ligation by accepted documented surgical procedural methods (Modified Pomeroy or Parkland method)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete Salpingectomy
Description: Patients will undergo a complete salpingectomy by a documented surgical protocol established by accepted surgical procedural methods.
Study: NCT03681028

Intervention type: DRUG
Group type: OTHER
Intervention: Individualized therapy
Description: 1. For a given proposed individualized combination of drugs the first priority to establish doses will be to identify the same combination of drugs in a peer-reviewed journal article or presented as a reviewed abstract.~2. When a proposed individualized combination of drugs has not previously been reported, the process to establish doses will be to then identify individual members of the proposed combination that have been used in combination with other cytotoxic agents similar to those being considered for combination therapy.~3. When a proposed individualized combination of drugs has no available combination data, dosing guidelines will start with the FDA-approved package insert recommended dose.
Study: NCT03911492

Intervention type: PROCEDURE
Group type: OTHER
Intervention: SCPP Management => 65 mmHg
Description: A lumbar intrathecal catheter will be inserted pre-operatively for the measurement of Intrathecal pressure (ITP) and the collection of cerebrospinal fluid (CSF) samples. SCPP will be calculated as the difference between Mean Arterial Pressure (MAP) and the ITP.
Study: NCT00740545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparine 40 mg daily
Description: Women inject ourselves every days with 40 mg of enoxaparine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Women inject ourselves every days with placebo
Study: NCT00605241

Intervention type: DRUG
Group type: OTHER
Intervention: GSK598809
Description: Drug
Study: NCT00820768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-010
Description: 17-AAG and ABI-007
Study: NCT03293823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VSOP training
Description: a computerized cognitive training of attention and processing speed

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MLA control
Description: a computerized cognitive intervention of multiple mental leisure activities
Study: NCT03414138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: A well-validated brief mindfulness-based mental training regimen \[four sessions; 20 min/session\] will be used to teach patients to independently practice mindfulness meditation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Book Listening Control
Description: Study volunteers will listen to four 20 minute blocks of The Natural History and Antiquities of Selborne throughout their interventions.
Study: NCT01777919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper
Study: NCT00206648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaferon/Betaseron
Description: Betaseron 250 µg SC every other day
Study: NCT03244397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy + educational strategy
Description: See arm/group descriptions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational strategy
Description: See arm/group descriptions
Study: NCT03256175

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: PCI technique (e.g. pre-dilatation vs. direct stenting and stent choice) was left to operator discretion. Stent post dilatation was permitted as per individual operator practice

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: PCI technique (e.g. pre-dilatation vs. direct stenting and stent choice) was left to operator discretion. Stent post dilatation was permitted as per individual operator practice
Study: NCT01090128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoparticle Albumin Bound Paclitaxel
Description: IV administered over 30 minutes. 100 mg/m2 on days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 500 mg/m2 given every 3 weeks
Study: NCT01407679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alitretinoin
Description: 1 capsule Alitretinoin 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
Study: NCT00923195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MART-1: 26-35(27L) Peptide
Description: Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14.
Study: NCT00206648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betaferon/Betaseron
Description: Avonex 30 µg IM once per week
Study: NCT02094703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Solifenacin succinate)
Study: NCT00923195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gp100:154-162 Peptide
Description: Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14.
Study: NCT02180646

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High protein breakfast
Description: a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High protein breakfast
Description: a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High carb breakfast
Description: a high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High carb breakfast
Description: a high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat)
Study: NCT00053833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Study: NCT06201182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMT via rectal enema
Description: 50 grams of FMT via rectal enema

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMT capsules
Description: FMT capsules given twice daily for 2 consecutive days
Study: NCT05999994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered orally
Study: NCT06201182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo via rectal enema
Description: Placebo via rectal enema

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo via rectal enema
Description: Placebo via rectal enema

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules
Description: Placebo capsules given twice daily for 2 consecutive days
Study: NCT00923195

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day -6 to -2: Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days
Study: NCT05999994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Administered orally
Study: NCT00923195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day -6 to -2: Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day -6 to -5: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna15 mg/kg/day over 1 hr X 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day -6 to -5: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna15 mg/kg/day over 1 hr X 2 days.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Anti-gp 100:154 TCR PBL
Description: Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or theMART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Anti-MART-1 F5 TCR PBL
Description: Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or theMART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14
Study: NCT03412019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Selections of Mozart piano sonatas
Study: NCT06201182

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsules given twice daily for 2 consecutive days
Study: NCT01673165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skimmed mother's milk
Description: Fortified skimmed mother's milk will be given to the skimmed mother's milk group. The fortifier is a standard fortifier we use in our population

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specialized Formula
Description: Infants will receive our standard of care - specialized formula
Study: NCT02172716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment
Description: All patients with GCP will receive full-mouth scaling and root planning under local analgesia in one session. Hopeless teeth will be treated similarly and extracted after de 30 days visit. Oral hygiene instructions will be given as needed.~Supragingival scaling Periodontally healthy subjects will receive supra-gingival scaling and polishing in one appointment as needed. Oral hygiene instructions will be given as needed.
Study: NCT00525031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: 150 mg/m\^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: 150 mg/m\^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alpha-2b (PGI)
Description: 0.5 mcg/kg subcutaneous injection once weekly for a total of 8 weeks.
Study: NCT01174641

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: trans-cranial magnetic stimulation
Description: 1 Hz trans-cranial magnetic stimulation will be applied for 20min at 60% motor threshold over the vertex

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trans-cranial magnetic stimulation
Description: trans-cranial magnetic stimulation will be applied at 1Hz for 20 min over the ipsilesional posterior parietal cortex of stroke patients with unilateral neglect
Study: NCT03227822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short spot stenting

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long lesion stenting
Study: NCT00975130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SC golimumab
Description: Subcutaneous golimumab at a dose of 50 mg administered once monthly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SC golimumab
Description: Subcutaneous golimumab at a dose of 50 mg administered once monthly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SC golimumab
Description: Subcutaneous golimumab at a dose of 50 mg administered once monthly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IV golimumab
Description: Intravenous golimumab administered up to 3 times (month 7, 8, 10) during a period of 6 months at a dose of 2 mg/kg of body weight.
Study: NCT02729194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat Diet
Description: Registered subjects will take pazopanib by mouth with a low-fat meal (containing less than 400 calories and less than 10% fat or 10 grams per meal.
Study: NCT01656954

Intervention type: PROCEDURE
Intervention: Passive Leg Raise (PLR)
Description: From the supine position, the legs are elevated to 45 degrees above the resting surface for a period of 3 minutes. At completion,the legs are lowered to the resting surface.
Study: NCT04324398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: cold application
Study: NCT04006977

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: a multistrain probiotic product (DSF)
Description: In Arm 2, participants will receive standard medical therapy plus the multistrain probiotics (DSF), 4 sachets per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Arm 1, participants will receive standard medical therapy plus the placebo.
Study: NCT03975283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel 266 MG Per 20 ML Injection
Description: 266mg of liposomal bupivacaine 266 mg, 20 mL volume, will be diluted with 20 ml of 0.25% bupivacaine (50 mg of bupivacaine) and 20 ml saline, thereby totalling 60mL volume. Total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.25% Inj
Description: 0.25% bupivacaine, 60mL total, divided into two 30mL syringes and delivered via TAP block on either side.
Study: NCT00746954

Intervention type: DRUG
Group type: OTHER
Intervention: Acetazolamide
Description: Cabonic Anhydrase inhibitor

Intervention type: DRUG
Group type: OTHER
Intervention: Acetazolamide
Description: Cabonic Anhydrase inhibitor

Intervention type: DRUG
Group type: OTHER
Intervention: Acetazolamide
Description: Cabonic Anhydrase inhibitor

Intervention type: DRUG
Group type: OTHER
Intervention: Buspirone
Description: Agonist of a 5-HT1a receptor with some D2 agonist properties.

Intervention type: DRUG
Group type: OTHER
Intervention: Buspirone
Description: Agonist of a 5-HT1a receptor with some D2 agonist properties.

Intervention type: DRUG
Group type: OTHER
Intervention: Buspirone
Description: Agonist of a 5-HT1a receptor with some D2 agonist properties.
Study: NCT02562755

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pexastimogene Devacirepvec (Pexa Vec)
Description: Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib belongs to the pharmacotherapeutic group of antineoplastic agents, protein kinase inhibitors, ATC code: L01XE05.~Sorafenib is a multi-kinase inhibitor which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo.~Sorafenib is approved for the treatment of advanced HCC and is the Standard Of Care for this disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib belongs to the pharmacotherapeutic group of antineoplastic agents, protein kinase inhibitors, ATC code: L01XE05.~Sorafenib is a multi-kinase inhibitor which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo.~Sorafenib is approved for the treatment of advanced HCC and is the Standard Of Care for this disease.
Study: NCT03419169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light load BFR resistance training
Description: A novel training light load resistance training modality.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heavy load resistance training
Description: A common form of resistance training used for rehabilitation within the National Health Service.
Study: NCT03157986

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance Training on a vibration platform
Description: n=24 patients with severe chronic obstructive pulmonary disease. Exercises will be performed on a side-alternating Vibration platform (Galileo) at frequencies between 15 to 26 Hertz.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Balance training
Description: n=24 patients with COPD, Exercises will be performed on a Balance pad